Food and nutrition security exists when all people at all times have access to nutritious food for the prevention and treatment of disease and the promotion of health and well-being. Food and ...

Dr. Carlos A. Portales Castillo (Medicine): A 30-year-old woman was admitted to this hospital because of headache and dysesthesia. The patient had been in her usual state of good health until 8 ...

Three of the authors served as editors-in-chief of MMWR: Dr. Rasmussen from 2015 to 2018, Dr. Lindegren from 2005 to 2006, and Dr. Altman from 1963 to 1964.Dr. Iademarco served as director of the ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

Most patients with extrapancreatic neuroendocrine tumors or pancreatic neuroendocrine tumors eventually have disease progression with available therapies, and new treatments are needed. New ...

In patients with acute myocardial infarction, treatment with the antiinflammatory agent colchicine may improve cardiovascular outcomes; however, results of clinical trials are mixed. New research ...

Whether the large effect size of endovascular thrombectomy (EVT) for stroke due to large-vessel occlusion applies to stroke due to medium-vessel occlusion is unclear. In a multicenter, prospective ...

Familial HLH is a success story in modern medicine. Initially a disease that was largely unknown and fatal, it is now understood on a molecular level and is curable. Moreover, HLH is an archetype ...

Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear. We randomly assigned ...

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case ...

Copyright © 2025 Massachusetts Medical Society. All rights reserved. For personal use only. Any commercial reuse of NEJM Group content requires permission.

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...